# Jazz Pharmaceuticals plc (JAZZ) · Edgar & Edgarette company card

> Jazz Pharmaceuticals (JAZZ) grew revenue 4.9% in FY2025 to $4.3 billion, operating margin -10.1% against a -3.8% median for pharmaceutical preparations, equity 37.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1232524 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/JAZZ) · [JSON](https://www.pops4.com/boards/company/JAZZ.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $4.3B |
| Revenue growth, 1 year | 4.9% |
| Revenue growth per year | 8.4% |
| Operating margin | -10.1% (prior year 17.6%) |
| Net margin | -8.3% |
| Operating cash flow | $1.4B |
| Capital spending | $59M |
| Free cash flow | $1.3B |
| Cash | $1.4B |
| Long-term debt | $5.4B |
| Total assets | $11.7B |
| Total equity | $4.3B |
| Equity ÷ assets | 37.0% |
| Return on equity | -8.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.63 (grey zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Sound ship · one warning sign · operating loss: a margin of -10.1% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $4.3B (FY2025), total debt $5.4B. Experience: revenue up 4.9% on the year, up 8.4% a year over 4 years; operating margin -10.1%, down from 17.6%. Soundness: equity 37.0% of assets, return on equity -8.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.9B and $4.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.7B to $5.2B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -10.1% against a -3.8% median; growth 4.9% against 13.7%.

Range logged 2026-09-26, receipt e93f16ccf8b2d452, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/0001628280-26-065497-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/0001232524-26-000057-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/0001232524-26-000056-index.htm)
- 8-K · filed 2026-10-26 · 2.02 Results of Operations and Financial Condition · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000162828026067275/0001628280-26-067275-index.htm)
- 8-K · filed 2026-10-09 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/0001628280-26-065497-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/0001193125-26-399425-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/0001628280-26-061978-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001232524.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1232524

## Cite

POPS4, Edgar & Edgarette: Jazz Pharmaceuticals plc (JAZZ) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/JAZZ. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.